Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models

MIEKO YANAGISAWA, KAORI FUJIMOTO-OUCHI, KEIGO YOROZU, YORIKO YAMASHITA and KAZUSHIGE MORI

Product Research Department, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan

Received February 20, 2009; Accepted March 30, 2009

DOI: 10.3892/or_00000430

Abstract. To understand the mechanisms of the effects of combination treatments, we established animal models showing antitumor activity of bevacizumab as a monotherapy and in combination with capecitabine or capecitabine and oxaliplatin and measured thymidine phosphorylase (TP) and vascular endothelial growth factor (VEGF) levels. Tumor-inoculated nude mice were treated with bevacizumab, capecitabine, and oxaliplatin, alone or in combination, after tumor growth was confirmed and volume and microvessel density (MVD) in tumors were evaluated. Levels of TP and VEGF in the tumor were examined by ELISA. Bevacizumab showed significant antitumor activity as a monotherapy in three xenograft models (COL-16-JCK, COLO 205 and CXF280). The MVD in tumor tissues treated with bevacizumab was lower than that of the control. Antitumor activity of bevacizumab in combination with capecitabine was significantly higher than that of each agent alone (COL-16-JCK, COLO 205). Furthermore, the antitumor activity of bevacizumab in combination with capecitabine + oxaliplatin was significantly superior to that of capecitabine + oxaliplatin (COL-16-JCK). TP and VEGF levels were not increased by bevacizumab or capecitabine, respectively, suggesting there are other potentially efficacious mechanisms involved. In the present study we established human colorectal cancer xenograft models which reflect the efficacy of clinical combination therapies, capecitabine + bevacizumab and capecitabine + oxaliplatin + bevacizumab. We will further investigate the mechanisms of the combination therapies using these models.

Introduction

Bevacizumab (Avastin®) is a genetically engineered humanized monoclonal antibody derived from murine anti-human vascular endothelial growth factor (VEGF) monoclonal antibody A4.6.1 (1,2). It binds specifically to human VEGF, thereby blocking the binding of VEGF to VEGF receptors expressed on vascular endothelial cells. By blocking the biological activity of VEGF (3), bevacizumab or its murine equivalent A4.6.1 inhibits neovascularization in tumor tissues and thus suppresses tumor growth (1). Clinically, it has been reported that bevacizumab significantly improved the survival benefit among patients with metastatic colorectal cancers in combination with irinotecan hydrochloride, fluorouracil, and leucovorin (IFL) and with fluorouracil and leucovorin (5-FU/LV) (6,7). Capecitabine (N4-pentyloxycarbonyl-5’-deoxy-5-fluorocytidine, Xeloda®) is an oral fluoropyrimidine drug widely used and is enzymatically metabolized to 5-FU by thymidine phosphorylase (TP) highly expressed in tumors. It has been reported that the antitumor activity of capecitabine correlates with tumor levels of TP activity in xenograft models (8).

A recent phase III study has reported that the combination therapy of bevacizumab with FOLFOX4 (bolus and infusional 5-FU/LV plus oxaliplatin) or with XELOX (capecitabine plus oxaliplatin) significantly improves progression free survival compared with FOLFOX4 or XELOX alone in first-line metastatic colorectal cancer (9). In our present study, we evaluated the antitumor activity of bevacizumab as a monotherapy and in combination with capecitabine alone and with capecitabine and oxaliplatin in human colorectal cancer xenograft models. To understand the mechanisms of the effects of the combination of bevacizumab and capecitabine, we measured the levels of TP and VEGF, which are determinants for efficacy of capecitabine and bevacizumab, respectively.

Materials and methods

Animals. Five-week-old male BALB-nu/nu (CAnN.Cg-Foxn1 <nu>/CrlCrlj nu/nu) mice were obtained from Charles River Laboratories Japan, Inc. (Kanagawa, Japan) and acclimatized for at least 1 week in our animal facility before use. The number of animals per experiment group was four to six, as
Tumors. Three human colorectal cancer lines were used in this study. COL-16-JCK was provided by the Central Institute for Experimental Animals (Kanagawa, Japan), COLO 205 (ATCC CCL-222) was purchased from American Type Culture Collection (Manassas, VA, USA) and CXF280 was kindly provided by Dr H.H. Fiebig (University of Freiburg, Freiburg, Germany). COL-16-JCK and CXF280 were maintained in BALB-nu/nu mice by subcutaneous inoculation of tumor pieces. COLO 205 was maintained in vitro in culture medium RPMI-1640 containing 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 4.5 g/l glucose, 1.5 g/l sodium bicarbonate and 10% FBS at 37°C in an incubator with 5% CO₂.

Human cancer xenograft models. Pieces (∼2x2 mm) of minced tumor tissue of COL-16-JCK and CXF280 were inoculated subcutaneously (s.c.) into the right flank region of male BALB-nu/nu mice. A suspension of COLO 205 cells (5x10⁶ or 8.8x10⁶ viable cells/mouse) was injected s.c. into a male BALB-nu/nu mouse. Treatments with the antitumor drugs were started after tumors were sufficiently established in the mice. Tumor volume was estimated using the equation

\[ V = \frac{a \times b^2}{2}, \]

where a and b are tumor length and width, respectively. The percentage of tumor growth inhibition was calculated as follows:

\[ \text{TGI} = \frac{1 - \text{Mean change in tumor volume in each group treated with antitumor drugs}}{\text{Mean change in tumor volume in the control group}} \times 100. \]

Immunohistochemistry. Tumor tissues were collected after treatment with bevacizumab or human IgG. Immunohistochemistry was performed using the standard method of avidin-biotin complex peroxidase staining on 4-μm thick sections from paraffin-embedded, formalin-fixed tissue. The CD34 antibody (rat monoclonal antibody, clone MEC14.7; Bioworld Technology, Uden, The Netherlands) (10) was used to identify the microvessels.

Microvessel density (MVD). MVD was determined as the ratio of the CD34-positive area to the total observation area. Four to six fields per section (0.4977 mm² each) were randomly analyzed, excluding necrotic areas. The CD34-positive areas within the viable regions were measured using imaging analysis software Win ROOF (Mitani Corporation, Fukui, Japan).

TP levels in the tumor. Tumor tissues were homogenized in 10 mM Tris-buffer (pH 7.4) containing 15 mM NaCl, 1.5 mM MgCl₂, and 50 μM potassium phosphate buffer using a glass homogenizer. The homogenate was then centrifuged at 10,000 x g for 15 min at 4°C and the supernatants were stored at -80°C until use. The protein concentration of the supernatants was determined using a DC protein assay kit (Bio-Rad, Hercules, CA, USA). The level of TP was measured by ELISA with monoclonal antibodies specific to human TP, as previously described by Nishida et al (11). One unit corresponds to the amount of TP enzyme activity, which phosphorylates 5'-DFUR to 5-FU at rate of 1 μg 5-FU per hour (recombinant human TP).

Levels of VEGF in tumors. Tumor tissues were homogenized in PBS buffer containing 0.05% Tween-20 using a glass homogenizer. The homogenized samples were then centrifuged at 10,000 x g for 20 min at 4°C and the supernatants were stored at -80°C until use. The protein concentration of the supernatants was determined using a DC protein assay kit (Bio-Rad). The level of VEGF was measured using a human VEGF ELISA kit (R&D, Minneapolis, MN, USA).

Chemicals. Bevacizumab (Avastin®) and capcitabine (Xeloda®) were obtained from F. Hoffman-La Roche Ltd. (Basle, Switzerland). Oxaliplatin was kindly provided by Sanofi-Synthelabo Inc. (presently Sanofi-Aventis). Human immunoglobulin G (HuIgG) was purchased from MP Biomedicals, Inc. (Solon, OH, USA). Bevacizumab and HuIgG were diluted with saline and administered intra-peritoneally (i.p.) twice a week for 3 weeks. Capcitabine was suspended in 40 mM citrate buffer (pH 6.0) containing 5% gum arabic as the vehicle and given orally (p.o.) for 14 days. Oxaliplatin was dissolved in 5% glucose solution and given intravenously (i.v.) once only on the day of treatment initiation.

Statistical analysis. Statistical analysis was performed using the Mann-Whitney U test. Differences were considered to be significant for values of P<0.05.

Results

Tumor growth inhibition by bevacizumab monotherapy. We examined the antitumor activity of bevacizumab monotherapy in three human colorectal cancer xenograft models. A piece of minced COL-16-JCK tumor tissue was inoculated s.c. into the right flank region of BALB-nu/nu mice. Twenty-one days after tumor inoculation, the mice were divided into 4 groups and treatment was initiated (Day 1). Bevacizumab at doses of 1.2, 2.5 and 4.0 mg/kg and HuIgG at 4.0 mg/kg as the control were administered i.p. twice a week for 3 weeks. Antitumor activity was evaluated on Day 22 (21 days after the treatment was initiated). TGI% was 46, 59 and 55% in the groups treated with bevacizumab at 1.2, 2.5 and 4.0 mg/kg, respectively. There were statistically significant differences in tumor volume between the control group and the groups treated with bevacizumab at doses of 1.2 mg/kg or above (P<0.05, Fig. 1a).

BALB-nu/nu mice were injected s.c. with 5x10⁶ cells of COLO 205 cell line into the right flank region. Nine days after the injection of the tumor cells, treatment was started. TGI% on Day 22 was 33, 41 and 44% in the groups treated with bevacizumab at doses of 1.2, 2.5 and 4.0 mg/kg, respectively. There were statistically significant differences in tumor volume between the control group and the groups treated with bevacizumab at doses of 1.2 mg/kg and above (P<0.05, Fig. 1b).

For mice inoculated with CXF280, treatment was initiated 18 days after inoculation. TGI% on Day 22 was 22, 40 and
47% in the groups treated with bevacizumab at doses of 0.4, 1.2 and 4.0 mg/kg, respectively. There were statistically significant differences in tumor volume between the control group and the groups treated with bevacizumab at doses of 1.2 mg/kg and above (P<0.05, Fig. 1c).

No significant decrease in body weight was observed in any of the groups of the three xenograft models (Fig. 1a, b and c).

Antitumor activity of bevacizumab in combination with capecitabine. We evaluated the antitumor activity of bevacizumab in combination with capecitabine in two human colorectal cancer xenograft models. Twenty-seven days after inoculation with COL-16-JCK tumors, the mice were divided into 4 groups (6 mice per group) and treatment was initiated (Day 1). Bevacizumab was administered i.p. at 4 mg/kg twice a week for 3 weeks and capecitabine was orally administered at 359 mg/kg [2/3 maximum tolerated dose (MTD)](8) daily for 14 days. On Day 37, there were statistically significant differences in tumor volume between the control and the groups treated with capecitabine, bevacizumab and bevacizumab in combination with capecitabine. There were also statistically significant differences in tumor volume between the group treated with bevacizumab in combination with capecitabine and the groups treated with bevacizumab and capecitabine alone (P<0.05, Fig. 2). TGI% on Day 37 was 52% in the capecitabine group, 35% in the bevacizumab group and 80% in the capecitabine + bevacizumab combination group.

COLO 205 colorectal cancer cells (8.8x10^6) were injected s.c. into the right flank region of BALB-nu/nu mice. Seven days after tumor cell injection, the mice were divided into
4 groups (6 mice per group) and treatment was initiated (Day 1). Bevacizumab was administered i.p. twice a week for 3 weeks and capecitabine was given p.o. daily for 14 days. Tumor volumes on Day 22 were significantly smaller in the capecitabine + bevacizumab group than in groups treated with each agent alone (P<0.05, Fig. 3). TGI% was 55% in the capecitabine group, 44% in the bevacizumab group and 82% in the capecitabine + bevacizumab combination group.

No significant difference in body weight was observed between mice treated with capecitabine + bevacizumab and those treated with each single agent in the COL-16-JCK and COLO 205 models (Figs. 2 and 3).

**Antitumor activity of bevacizumab in combination with capecitabine + oxaliplatin.** The mice inoculated with COL-16-JCK were divided into 6 groups (6 mice per group); 25 days after tumor inoculation treatments were initiated (Day 1). Capecitabine was administered p.o. at 180 mg/kg (1/3 MTD) (8) daily for 14 days. Oxaliplatin was administered i.v. at 5 mg/kg (1/3 MTD) (12) on Day 1 and 4 mg/kg of bevacizumab was administered i.p. twice a week for 3 weeks. On Day 36, bevacizumab and capecitabine significantly inhibited tumor growth as single agent. TGI% was 38% in the capecitabine group, 23% in the oxaliplatin group and 70% in the capecitabine + oxaliplatin group (Fig. 4). Capecitabine in
Combination with oxaliplatin showed significantly higher antitumor activity than capecitabine, although oxaliplatin as a single agent showed no significant antitumor activity. Furthermore, the antitumor activity of bevacizumab in combination with capecitabine + oxaliplatin (TGI: 86%) was significantly superior to that of capecitabine + oxaliplatin (TGI: 70%) and that of bevacizumab alone (TGI: 44%). No significant difference in body weight was observed between mice treated with capecitabine + oxaliplatin alone and those treated with capecitabine + oxaliplatin + bevacizumab (Fig. 5).

Effect of bevacizumab on MVD. We investigated the effect of bevacizumab on microvessel density (MVD) in tumor tissues of the COL-16-JCK xenograft model by using immunohistochemical staining for CD34. Bevacizumab at doses of 1.2 and 4.0 mg/kg and HuIgG at 4.0 mg/kg as a control were administered i.p. twice a week for 3 weeks (41 days post-tumor inoculation). Tumor tissues were collected 5 days after the last treatment (Day 23). TGI% was, respectively, 43 and 45% in the groups treated with bevacizumab at 1.2 and 4.0 mg/kg on Day 23. Typical immunohistochemical staining images of CD34 are shown in Fig. 6. The MVD was determined as the ratio of the CD34-positive area to the total observation area using imaging analysis software, Win ROOF. *P<0.05 (n=4).

Table I. Levels of TP from treatment with bevacizumab and VEGF from treatment with capecitabine in COL-16-JCK and COLO 205 xenografts.a

<table>
<thead>
<tr>
<th>Cell line</th>
<th>HuIgG (4 mg/kg)</th>
<th>Bevacizumab (4 mg/kg)</th>
<th>Vehicle</th>
<th>Capecitabine (539 mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>COL-16-JCK</td>
<td>2.1±0.7</td>
<td>2.7±5.8</td>
<td>281.2±36.0</td>
<td>272.0±21.3</td>
</tr>
<tr>
<td>COLO 205</td>
<td>8.5±0.6</td>
<td>9.5±2.4</td>
<td>NT</td>
<td>NT</td>
</tr>
</tbody>
</table>

*aHuIgG or bevacizumab was administered i.p. twice a week for 3 weeks. Capecitabine was given p.o. daily for 13 days. The levels of TP and VEGF in tumor tissue were measured by ELISA. NT, not tested.

Levels of TP and VEGF in tumor tissues. We measured the levels of TP and human VEGF in tumor tissues in COL-16-JCK and COLO 205 xenograft models. Levels of tumor TP were not changed after i.p. administration of bevacizumab at 4 mg/kg twice a week for 3 weeks in the COL-16-JCK and COLO 205 xenograft models. The level of VEGF in tumor was not increased by capecitabine treatment (539 mg/kg, daily for 13 days) in the COL-16-JCK model (Table I).
Discussion

In our present study, we demonstrated the antitumor activity of bevacizumab as a monotherapy and in combination therapies with capecitabine and capecitabine + oxaliplatin in human colorectal cancer xenograft models. The antitumor activity of bevacizumab in combination with capecitabine was significantly higher than that of bevacizumab monotherapy in 2 xenograft models. In addition, we investigated the mechanisms of the combination effects of bevacizumab and capecitabine in the 2 xenograft models.

Capecitabine is enzymatically metabolized to 5-FU as a result of the highly expressed TP in the tumor. It has been reported that the antitumor activity of capecitabine correlates with tumor levels of TP activity in xenograft models (8). Some chemotherapeutic drugs, such as the taxanes, have been reported to increase the levels of TP in tumors in xenograft models and to show significantly more potent antitumor activity in combination with capecitabine than each agent as a monotherapy (12-14). It has been also reported that oxaliplatin treatment increased the level of TP in tumor tissues in xenograft models (15). In the present study, we investigated the levels of TP in tumors after treatment with bevacizumab to evaluate possible therapeutic effects in combination with capecitabine and with capecitabine + oxaliplatin in xenograft models. However, bevacizumab induced no significant increase in levels of TP in the 2 xenograft models used, suggesting that the combination effects are a result of mechanisms other than TP up-regulation in tumors treated with bevacizumab. A4.6.1 has been reported to increase pO2 in tumor tissues (16). On the other hand, hypoxia has been reported to induce TP in tumor cells (17) and might explain the lack of an increase in the levels of TP in the tumor after treatment with bevacizumab in the xenograft models tested.

Bevacizumab binds to human VEGF and inhibits its biological activities. VEGF has been reported to be expressed in tumor tissues and to play a major role in tumor angiogenesis (18-21). As in many studies, the present study also demonstrated that bevacizumab decreased microvessel density in the tumor tissues of the xenograft models. In tumors expressing VEGF, tumor growth would be more dependent on angiogenesis regulated by VEGF. Therefore, we investigated the level of VEGF after treatment with capecitabine to possibly explain the mechanisms of the effects of bevacizumab and capecitabine in combination. However, no significant increase in tumor VEGF was demonstrated after treatment with bevacizumab to possibly explain the mechanisms of the effects of bevacizumab and capecitabine in combination. We will further investigate the mechanisms of combination therapies plus bevacizumab in xenograft models that show effects of anti-tumor activity.

Acknowledgements

We thank Sanofi Synthelabo (presently Sanofi-Aventis) for providing oxaliplatin, Dr H.H. Fiebig of Freiburg University, Germany for providing the CXF280 cell line and Ms. F. Ford for English language proofreading.

References


